Literature DB >> 9576119

Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives.

M R Weir1, S G Chrysant, D A McCarron, M Canossa-Terris, J D Cohen, P A Gunter, A J Lewin, R F Mennella, L W Kirkegaard, J H Hamilton, M H Weinberger, A B Weder.   

Abstract

Dietary salt restriction is a recommended adjunct with antihypertensive therapy. There may be racial differences in blood pressure response to salt restriction while on antihypertensive therapy. We performed a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial (black, n=96; Hispanic, n=63; white, n=232). Participants were initially preselected for stage I to III hypertension and then further selected for salt sensitivity (> or = 5 mm Hg increase in diastolic blood pressure after 3 weeks of low salt [< or = 88 mmol/d Na+] and high salt [>190 mmol/d Na+] diet). We compared the antihypertensive effect of an angiotensin-converting enzyme inhibitor (enalapril 5 or 20 mg BID) or a calcium channel antagonist (isradipine 5 or 10 mg BID) during alternating periods of high and low salt intake. The main outcome measure was blood pressure change and absolute blood pressure level achieved with therapy. During the high salt diet (314.7+/-107.5 mmol/d urinary Na+) there was greater downward change in blood pressure with both enalapril and isradipine compared with the low salt diet (90.1+/-50.8 mmol/d Na+); however, the absolute blood pressure achieved in all races was consistently lower on a low salt diet for both agents. Black, white, and Hispanic isradipine-treated salt-sensitive hypertensives demonstrated a smaller difference between high and low salt diets (black, -3.6/-1.6 mmHg; white, -6.2/-3.9 mmHg; Hispanic, -8.1/-5.3 mm Hg) than did enalapril-treated patients (black, -9.0/-5.3 mm Hg; white, -11.8/-7.0 mm Hg; Hispanic, -11.1/-5.6 mm Hg). On the low salt diet, blacks, whites, and Hispanics had similar blood pressure control with enalapril and isradipine. On the high salt diet, blacks had better blood pressure control with isradipine than with enalapril, whereas there was no difference in the blood pressure control in whites and Hispanics treated with either drug. Dietary salt reduction helps reduce blood pressure in salt-sensitive hypertensive blacks, whites, and Hispanics treated with enalapril or isradipine. These data demonstrate that controlling for salt sensitivity diminishes race-related differences in antihypertensive activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9576119     DOI: 10.1161/01.hyp.31.5.1088

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  36 in total

Review 1.  Management of hypertension in ethnic minorities.

Authors:  Jawad M Khan; D Gareth Beevers
Journal:  Heart       Date:  2005-08       Impact factor: 5.994

2.  Renal tubular angiotensin converting enzyme is responsible for nitro-L-arginine methyl ester (L-NAME)-induced salt sensitivity.

Authors:  Jorge F Giani; Masahiro Eriguchi; Ellen A Bernstein; Makoto Katsumata; Xiao Z Shen; Liang Li; Alicia A McDonough; Sebastien Fuchs; Kenneth E Bernstein; Romer A Gonzalez-Villalobos
Journal:  Kidney Int       Date:  2016-12-15       Impact factor: 10.612

3.  Treating Hypertension in Children With n-of-1 Trials.

Authors:  Joyce P Samuel; Jon E Tyson; Charles Green; Cynthia S Bell; Claudia Pedroza; Don Molony; Joshua Samuels
Journal:  Pediatrics       Date:  2019-03-06       Impact factor: 7.124

Review 4.  Role of diet in hypertension management.

Authors:  Kevin M O'Shaughnessy
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

Review 5.  Salt handling and hypertension.

Authors:  Kevin M O'Shaughnessy; Fiona E Karet
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

6.  CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.

Authors:  Vibha Bhatnagar; Erin P Garcia; Daniel T O'Connor; Victoria H Brophy; John Alcaraz; Erin Richard; George L Bakris; John P Middleton; Keith C Norris; Jackson Wright; Leena Hiremath; Gabriel Contreras; Lawrence J Appel; Michael S Lipkowitz
Journal:  Am J Nephrol       Date:  2009-11-12       Impact factor: 3.754

Review 7.  Salt sensitivity and hypertension.

Authors:  Olga Balafa; Rigas G Kalaitzidis
Journal:  J Hum Hypertens       Date:  2020-08-29       Impact factor: 3.012

Review 8.  Salt sensitivity: a review with a focus on non-Hispanic blacks and Hispanics.

Authors:  Safiya I Richardson; Barry I Freedman; David H Ellison; Carlos J Rodriguez
Journal:  J Am Soc Hypertens       Date:  2013-02-19

9.  Association between dietary sodium and potassium intake with chronic kidney disease in US adults: a cross-sectional study.

Authors:  Shailendra Sharma; Kim McFann; Michel Chonchol; Ian H de Boer; Jessica Kendrick
Journal:  Am J Nephrol       Date:  2013-05-15       Impact factor: 3.754

10.  Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes.

Authors:  Allison B Rosen; Andrew J Karter; Jennifer Y Liu; Joe V Selby; Eric C Schneider
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.